Proposal To Fund An Additional Brand Of Budesonide With Eformoterol Dry Powder Inhaler NZNO warmly invites your feedback on PHARMAC’s proposal to fund an additional brand (DuoResp Spiromax) of two of the three funded strengths of budesonide with eformoterol dry powder inhaler from 1 October 2020 through a provisional agreement with Teva Pharmaceuticals Ltd ("Teva"). Further information can be seen here. Please note the short consultation timeframe. If the Policy Team receives no feedback, NZNO will not make a submission. Please send feedback to PolicyAnalysts@nzno.org.nz by 10 August 2020.